Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Oct 6;7(1):48.
doi: 10.1186/s13321-015-0096-0. eCollection 2015 Dec.

Modeling enzyme-ligand binding in drug discovery

Affiliations
Review

Modeling enzyme-ligand binding in drug discovery

Janez Konc et al. J Cheminform. .

Abstract

Enzymes are one of the most important groups of drug targets, and identifying possible ligand-enzyme interactions is of major importance in many drug discovery processes. Novel computational methods have been developed that can apply the information from the increasing number of resolved and available ligand-enzyme complexes to model new unknown interactions and therefore contribute to answer open questions in the field of drug discovery like the identification of unknown protein functions, off-target binding, ligand 3D homology modeling and induced-fit simulations.

Keywords: Drug repositioning; Induced-fit simulations; Ligand 3D homolgy modeling; Off-target binding; ProBiS-ligands web server; Unknown protein fuctions.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart of binding site comparison with subsequent ligand transposition
Fig. 2
Fig. 2
Ligand homology modeling using ProBiS-ligands web server on the example of butyrylcholinesterase enzyme (PDB code: 4tpk). On the right side of the screen is the list of predicted ligands with their corresponding Z-scores, specificities and PDB codes of protein structures from which they were transposed. The selected ligand’s row is highlighted orange. On the left side is the Jsmol viewer that contains the three-dimensional pose of the selected predicted ligand (galantamine, sticks, violet) and the predicted binding amino-acid residues (sticks, CPK colors, black labels)

References

    1. Yuriev E, Ramsland PA. Latest developments in molecular docking: 2010–2011 in review. J Mol Recognit. 2013;26:215–239. doi: 10.1002/jmr.2266. - DOI - PubMed
    1. Rose PW, et al. The RCSB Protein Data Bank: redesigned web site and web services. Nucleic Acids Res. 2011;39:D392–D401. doi: 10.1093/nar/gkq1021. - DOI - PMC - PubMed
    1. Haupt VJ, et al. Drug promiscuity in PDB: protein binding site similarity is key. PLoS one. 2013;8:e65894. doi: 10.1371/journal.pone.0065894. - DOI - PMC - PubMed
    1. Škedelj V, et al. 6-Arylpyrido[2,3-d]pyrimidines as novel ATP-competitive inhibitors of bacterial d-alanine:d-alanine ligase. PLoS One. 2012;7:e39922. doi: 10.1371/journal.pone.0039922. - DOI - PMC - PubMed
    1. Strittmatter SM. Overcoming drug development bottlenecks with repurposing: old drugs learn new tricks. Nat Med. 2014;20:590–591. doi: 10.1038/nm.3595. - DOI - PMC - PubMed

LinkOut - more resources